who are we

ATUM has been providing tools and solutions to Life Science researchers for over fifteen years. Our products, services and most importantly our people enable scientists worldwide to achieve their goals.

the leadership team

Claes Gustafsson, Ph.D.
Chief Commercial Officer
As ATUM’s Co-Founder and CCO, Dr. Gustafsson oversees most of the company's external communications. Prior to co-founding ATUM, Dr. Gustafsson led, managed and collaborated with key strategic teams at Maxygen Inc. Before Maxygen, Dr. Gustafsson worked as a scientist at Kosan Biosciences, a number of research, teaching, and post-doctoral positions at UCs Santa Cruz and San Francisco, and at University of Umeå. He received his Ph.D. in Molecular Biology/Biochemistry from the University of Umeå, Sweden.
Ferenc Boldog, Ph.D.
Director, Cell Line Development
Dr. Ferenc Boldog joined ATUM in 2016 and has brought his expertise and creativity to the company's molecular biology, cell biology and protein therapeutics development processes. Prior to ATUM, he was the Head of Cell Line Development at Shire. Throughout his 35-year academic and industrial career, Ferenc's passion has been science and innovation.
Jeremy Minshull, Ph.D.
Chief Executive Officer
Dr. Jeremy Minshull has served as President/CEO of ATUM since co-founding the company in 2003. Previously, he was Vice President of Core Technology at Maxygen Inc. Dr. Minshull has received his degree in Natural Sciences and his Ph.D. from the University of Cambridge, England, and performed post-doctoral work at UC San Francisco.
Jon Ness Ph.D.
Chief Scientific Officer
Dr. Jon Ness is a co-founder of ATUM and has coordinated ATUM's technology development since its inception. Prior to his tenure at ATUM, Dr. Ness was one of the first employees at Maxygen Inc., where he led Maxygen's DNA Shuffling Technology Development Group. Dr. Ness received a Ph.D. in Bacterial Genetics and Physiology from UC Davis, and a BS in Microbiology from the University of Minnesota. He conducted his post-doctoral research at Affymax, Inc.
Mark Fox, Ph.D.
Director, Protein Technologies
Dr. Mark Fox joined ATUM in 2017. Prior to his current position, Dr. Fox led the expression and purification groups at Catalyst Biosciences developing methods for the production of novel proteases and was a Principal Scientist at Rinat Laboratories, Pfizer inc. Before entering industry, Mark conducted Post graduate level research at the University of California, San Francisco and at the University of Washington. He received his Ph.D. in Molecular Parasitology from the University of Glasgow and holds a Masters and Undergraduate degree from the same University.
Mark Welch, Ph.D.
VP, Research and Development
Dr. Mark Welch has been with ATUM since 2006. At ATUM, Dr. Welch developed the GeneGPS machine-learning technology for experiment-driven gene expression optimization. He currently oversees gene, protein, vector and strain engineering contracts for customers as well as new technology development. Prior to work at ATUM, Dr. Welch held positions at Applied Biosystems and at Maxygen, Inc. Dr. Welch received his Ph.D. at the University of Colorado at Boulder.
Oren Beske, Ph.D.
SVP, Corporate Strategy and Development
Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc. where he led a multidisciplinary team to bring value added services to the biologics industry. Most recently, he served as the CEO of Alloy Therapeutics, Inc. a start up antibody discovery platform company. Dr. Beske received a BS in Physiology and Biochemistry from CSULB and his Ph.D. in Cell Biology from UC San Francisco.
Sridhar Govindarajan, Ph.D.
Chief Information Officer
As ATUM’s Co-founder and CIO, Dr. Sridhar Govindarajan leads the company's automation and protein engineering efforts. He has more than 20 years of scientific computing experience. Prior to his current position, Govindarajan led the computational research in optimizing directed evolution technologies at Maxygen, Inc., and was a Systems Architect at EraGen Biosciences. Dr. Govindarajan was a Junior Research Fellow at the Indian Institute of Technology (IIT)'s Department of Chemistry and received his PhD in Computational Chemistry/Biophysics from the University of Michigan's Department of Chemistry.

Founded in 2003 as DNA2.0, ATUM has built on its DNA design and synthesis expertise to develop an integrated pipeline of solutions for the research community.

With a reverence for the interplay between science, technology and nature, ATUM's unique and proprietary engineering platform is based on Design of Experiment (DoE), empirical testing and machine learning. The result is the precise engineering of commercially relevant properties in genes, vectors, proteins and cell lines.

ATUM emphasizes customer service as a critical measure of success. We aim to be a resource and research partner for scientists, to enable accurate and innovative delivery of specific, immediately useful solutions. Customers value the individual scientist-to-scientist support they receive from ATUM's technical sales and support staff, as well as the speed, accuracy, and flexibility with which products and services are delivered. ATUM's freely downloadable software tool Gene Designer and the online DNA ATLAS, give you the DNA sequence manipulation and management tools that we use in-house.

ATUM is based in the US, with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. ATUM is by far the most published synthetic biology vendor, providing expert support to and collaboration with scientists. The company is privately held and is headquartered in Newark, California.